877614-96-5Relevant academic research and scientific papers
An inhibitor of fatty acid synthase thioesterase domain with improved cytotoxicity against breast cancer cells and stability in plasma
Lupien, Leslie E.,Dunkley, Evan M.,Maloy, Margaret J.,Lehner, Ian B.,Foisey, Maxwell G.,Ouellette, Maddison E.,Lewis, Lionel D.,Pooler, Darcy Bates,Kinlaw, William B.,Baures, Paul W.
, p. 171 - 185 (2019/11/02)
It is well recognized that many cancers are addicted to a constant supply of fatty acids (FAs) and exhibit brisk de novo FA synthesis. Upregulation of a key lipogenic enzyme, fatty acid synthase (FASN), is a near-universal feature of human cancers and their precursor lesions, and has been associated with chemoresistance, tumor metastasis, and diminished patient survival. FASN inhibition has been shown to be effective in killing cancer cells, but progress in the field has been hindered by off-target effects and poor pharmaceutical properties of candidate compounds. Our initial hit (compound 1) was identified from a high-throughput screening effort by the Sanford-Burnham Center for Chemical Genomics using purified FASN thioesterase (FASN-TE) domain. Despite being a potent inhibitor of purified FASN-TE, compound 1 proved highly unstable in mouse plasma and only weakly cytotoxic to breast cancer (BC) cells in vitro. An iterative process of synthesis, cytotoxicity testing, and plasma stability assessment was used to identify a new lead (compound 41). This lead is more cytotoxic against multiple BC cell lines than tetrahydro-4-methylene-2S-octyl-5-oxo-3R-furancarboxylic acid (the literature standard for inhibiting FASN), is stable in mouse plasma, and shows negligible cytotoxic effects against nontumorigenic mammary epithelial cells. Compound 41 also has drug-like physical properties based on Lipinski’s rules and is, therefore, a valuable new lead for targeting fatty acid synthesis to exploit the requirement of tumor cells for fatty acids.
Identification and SAR of Glycine Benzamides as Potent Agonists for the GPR139 Receptor
Dvorak, Curt A.,Coate, Heather,Nepomuceno, Diane,Wennerholm, Michelle,Kuei, Chester,Lord, Brian,Woody, David,Bonaventure, Pascal,Liu, Changlu,Lovenberg, Timothy,Carruthers, Nicholas I.
, p. 1015 - 1018 (2015/09/22)
A focused high throughput screening for GPR139 was completed for a select 100K compounds, and new agonist leads were identified. Subsequent analysis and structure-activity relationship studies identified (S)-3-chloro-N-(2-oxo-2-((1-phenylethyl)amino)ethyl
Stereodivergent synthesis of chiral fullerenes by [3 + 2] cycloadditions to C60
Maroto, Enrique E.,Filippone, Salvatore,Suarez, Margarita,Martinez-Alvarez, Roberto,De Cozar, Abel,Cossio, Fernando P.,Martin, Nazario
, p. 705 - 712 (2014/02/14)
A wide range of new dipoles and catalysts have been used in 1,3-dipolar cycloadditions of N-metalated azomethine ylides onto C60 yielding a full stereodivergent synthesis of pyrrolidino[60]fullerenes with complete diastereoselectivities and ver
